Meta-analysis of pramipexole in treatment of restless legs syndrome

( views:142, downloads:0 )
Author:
WANG Lei(Department of Neurology, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022, China)
XIAO Hai-bing()
YAN Dan(Department of Neurology, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022, China)
SU Ying(Department of Neurology, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022, China)
SUN Sheng-gang(Department of Neurology, Union Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430022, China)
Journal Title:
Chinese Journal of Neurology
Issue:
Volume 45, Issue 03, 2012
DOI:
10.3760/cma.j.issn.1006-7876.2012.03.010
Key Word:
Restless legs syndrome;Benzothiazoles;Meta-analysis

Abstract: Objective To evaluate the efficacy and safety of pramipexole in treating restless legs syndrome (RLS).Methods A search for randomized,double-blind,and placebo-controlled clinical trials of pramipexole in treating moderate to severe RLS using CNKI,PubMed,Embase and Cochrane Library database was carried out. A meta-analysis of included clinical trials was performed with RevMan 5.0 software.The 2 outcomes that the weighted mean difference(WMD) of change from baseline in International RLS Study Group rating scale(IRLS) score and the relative risk (RR) of response based on the Clinical Global Impression-Improvement (CGI-I) scale score were calculated for efficacy.Safety was assessed with RR of the adverse event (AE).Results A total of 5 clinical trials were included in this meta-analysis,of which 1776 patients were randomly assigned (945 on pramipexole,831 on placebo).The records of patients were pooled.Overall WMD were - 6.34 ( Z =12.76,P < 0.01 ) for the change from baseline in IRLS score,and RR of response based on CGI-I were 1.65 (Z =10.39,P <0.01).The overall RR of pramipexole versus placebo were 1.14 ( Z =1.87,P =0.06 ) for AE.Conclusion To treat RLS,pramipexole is an effective and safe drug.

  • [1]Allen RP, Picchietti D, Hening WA,et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology.A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.Sleep Med,2003,4:101-119.
  • [2]Schapira AH. Restless legs syndrome:an update on treatment options.Drugs,2004,64:149-158.
  • [3]Tison F,Crochard A,Léger D,et al.Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study.Neurology,2005,65:239-246.
  • [4]H(o)gl B,Kiechl S,Willeit J,et al.Restless legs syndrome:a community-based study of prevalence,severity,and risk factors.Neurology,2005,64:1920-1924.
  • [5]Mizuno S,Miyaoka T,Inagaki T,et al.Prevalence of restless legs syndrome in non-institutionalized Japanese elderly.Psychiatry Clin Neurosci,2005,59:461-465.
  • [6]Kim J,Choi C,Shin K,et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population:the Korean Health and G,enome Study.Psychiatry Clin Neurosci,2005.59:350-353.
  • [7]史洁,耿同超.不安腿综合征.中华神经科杂志,2006,39:493-495.
  • [8]Winkelman JW,Sethi KD,Kushida CA,et al.Efficacy and safety of pramipexole in restless legs syndrome.Neurology,2006,67:1034-1039.
  • [9]Partinen M,Hirvonen K,Jama L,et al.Ffficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study-the PRELUDE study.Sleep Med,2006,7:407-417.
  • [10]Oertel WH,Stiasny-Kolster K,Bergtholdt B,et al.Efficacy of pramipexole in restless legs syndrome:a six-week,multicenter,randomized,double-blind study (effreet-RLS study).Mov Disord,2007,22:213-219.
  • [11]Ferini-Strambi L,Aarskog D,Partinen M,et al. Effect of pramipexole on RLS symptoms and sleep:a randomized,doubleblind,placebo-controlled trial.Sleep Med,2008,9:874-881.
  • [12]Montagna P,Hornyak M,Ulfberg J,et al.Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.Sleep Med,2011,12:34-40.
  • [13]刘鸣.系统评价、Meta-分析设计与实施方法.北京:人民卫生出版社,2011:200.
  • [14]Walters AS,LeBrocq C,Dhar A,et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome.Sleep Med,2003,4:121-132.
  • [15]National Institute of Mental Health. CGI Clinical Global Impressions (CGI)//Guy W. ECD-EU assessment for psychopharmacology. Rockville: National Institute of Mental Health,1976:217-222.
  • [16]Quilici S,Abrams KR,Nicolas A,et al.Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.Sleep Med,2008,9:715-726.
  • [17]Zintzaras E,Kitsios GD,Papathanasiou AA,et al.Randomized trials of dopamine agonists in restless legs syndrome:a systematic review,quality assessment,and meta-analysis.Clin Ther,2010,32:221-237.
  • [18]Trenkwalder C,Stiasny-Kolster K,Kupsch A,et al.Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.Mov Disord,2006,21:1404-1410.
  • [19]Jams L,Hirvonen K,Partinen M,et al.A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome:polysomnographic evaluation of periodic leg movements and sleep disturbance.Sleep Med,2009,10:630-636.
  • [20]中华医学会神经病学分会帕金森病及运动障碍学组.不宁腿综合征的诊断标准和治疗指南.中华神经科杂志,2009,42:709-711.
  • [21]Inoue Y,Hiraat K,Kuroda K,et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: a polysomnographic randomized, double-blind,placebo-controlled study.Sleep Med,2010,11:11-16.
  • [22]Inoue Y,Hirata K,Kuroda K,et al.Efficacy,safety and doseresponse of pramipexole in Japanese patients with primary restless legs syndrome:randomized trial.Neuropsychobiology,2011,63:35-42.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn